Tell your caregiver right away if you feel light-headed or itchy, or if you have a fever, chills, neck or chest pain, new or worsening cough, feeling short of breath;new or worsening skin rash, itching, or blistering;problems in other organs--mood or behavior changes, neck stiffness, confusion, liver problems--loss of appetite, upper stomach pain, drowsiness, easy bruising or bleeding, dark urine, kidney problems--little or no urination, red or pink urine, swelling in your feet or ankles; orsigns of a hormonal disorder--unusual headaches, feeling light-headed or very tired, hoarse or deepened voice, increased hunger or thirst, increased urination, Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.This is not a complete list of side effects and others may occur. The PD-L1 inhibitor durvalumab has been approved to treat patients with stage III NSCLC and, in combination with platinum-etoposide, to treat patients with extensive-stage small cell lung cancer (ES-SCLC). Results from a new clinical trial show that adding the immunotherapy drug durvalumab (Imfinzi) to chemotherapy can improve how long some people with small cell lung cancer live.New results from a large clinical trial show that the Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease, said Anna Farago, M.D., Ph.D., a lung cancer specialist at Massachusetts General Hospital Cancer Center, who was not involved in the trial. patients in the third treatment group, for whom results have not yet been reported. The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation). by NCI Staff IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy. Checkpoint inhibitors that have been approved for some types of advanced non-small cell lung cancer (NSCLC) include atezolizumab, durvalumab, nivolumab and pembrolizumab.
Once the proteins are blocked, the immune cells can attack the cancer. Durvalumab is used to treat cancer of the lungs, bladder, or urinary tract. IMFINZI ® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). Call your doctor for medical advice about side effects. Durvalumab is used to treat cancer of the lungs, bladder, or urinary tract.Durvalumab is sometimes given when the cancer has spread to other parts of the body or cannot be removed with surgery, or when other treatments did not work or have stopped working.Durvalumab may also be used for purposes not listed in this medication guide.Durvalumab may cause serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, pituitary, or adrenal glands.Tell your doctor if you have an active infection, or if you have ever had:Durvalumab is given as an infusion into a vein, usually once every 2, 3 or 4 weeks. Select one or more newsletters to continue. by NCI Staff Durvalumab is sometimes given when the cancer has spread to other parts of the body or cannot be removed with surgery, or when other treatments did not work or have stopped working.